Twitxy Saved

Eduardo Marban, MD, PhD

Verified account This account is verified. Learn more

@MarbanLab

Dr. Eduardo Marban | Executive Director, Smidt Heart Institute @CedarsSinai Views are my own, not institutional policy!
Cedars-Sinai Medical Center cedars-sinai.edu/research/labs/… Joined May 2021
381 Following 2K Followers 1.4K Posts

Latest posts 5

Eduardo Marban, MD, PhD Verified account @MarbanLab
Real treat at today’s lab meeting. Superstar Asst Prof Alessandra Ciullo @AleCiulloPhD presented her innovative work on #exomer therapy (one of our novel #ncRNA drugs) for #Freidreich’s #ataxia, a triplet repeat genetic disorder affecting both the #cerebellum (causing shakes and postural instability) and the heart (lethal #cardiomyopathy). First demonstration of exomer efficacy in a #mitochondrial disease! 👍👏
1 replies 3 reposts 24 likes 869 views View on X
Eduardo Marban, MD, PhD Verified account @MarbanLab
Rigorous studies of deramiocel’s efficacy in @Duchenne @cardiomyopathy. Strong evidence of disease-modifying bioactivity in advanced @DMD, especially in the prespecified subgroup of HOPE-3 subjects with cardiomyopathy at baseline. Progression totally halted over one year of follow-up, with a trend towards net improvement— contrary to the relentless progression of dysfunction and scar in the placebo group. Congrats Jon Soslow, Chet Vila and team!
Capricor Therapeutics Verified account @Capricor Nov 9
This weekend at the American Heart Association Scientific Sessions 2026, Dr. Jonathan Soslow of Vanderbilt received the Outstanding Research Award in Pediatric Cardiology for his presentation of the HOPE-3 cardiac results for Deramiocel in Duchenne muscular dystrophy. Congratulations, Dr. Soslow, and thank you to the patients, families and investigators who made this research possible.
Read the press release: bit.ly/4BMIYM5
#AHA26 #Duchenne #DMD #ScientificSessions26 #Deramiocel $CAPR
View quoted post on X
3 replies 16 reposts 79 likes 9.6K views View on X
Eduardo Marban, MD, PhD Verified account @MarbanLab
.@FDA has proclaimed their innovative, proactive approach to rare diseases, but will they deliver? By any measure, #deramiocel exceeds the typical burden of evidence for efficacy and safety in a rare disease, with no less than 5 positive clinical trials. But FDA has yet to approve this novel cell therapy for #Duchenne muscular dystrophy. Meanwhile, boys and young men with advanced #DMD—precisely those who stand to benefit most from deramiocel—are awaiting this potentially transformational therapy. It’s time for FDA to do more than talk about rare diseases! The 28 authors of our recent @TheLancet HOPE-3 paper wrote the attached letter making these points to @FDA-- have a look!
Link for full letter lnkd.in/p/gptcbDKX
7 replies 17 reposts 86 likes 2.7K views View on X